Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Iberdomide has the potential to be the first approved CELMoD agent
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Harbour BioMed brings advanced antibody discovery platforms to the table
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Subscribe To Our Newsletter & Stay Updated
